Gastroenteropancreatic Neuroendocrine Tumor Clinical Trial
Official title:
The Clinical Utility of a Blood-Based Multitranscriptome Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
Verified date | July 2021 |
Source | H. Lee Moffitt Cancer Center and Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to evaluate how well an investigational blood test performs. The study will look at the sensitivity and specificity of a blood-based multitranscriptome assay (NETest).
Status | Completed |
Enrollment | 105 |
Est. completion date | September 15, 2020 |
Est. primary completion date | August 24, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: NET Cohort- - Patients with histologically or cytologically proven diagnosis of any grade, any stage NET of GEP or lung origin; In the first stage of the study (initial 50 patients) only patients with stage IV, well-differentiated tumors (G1/G2) will be enrolled. - Patients with stable or progressive disease, as documented on a scan (CT, MRI); Progression status will be documented on case report form (CRF). - Allowed prior therapies include: a.) Surgery (tumor surgery at least four weeks prior to study entry); b.) Locoregional therapy such as: chemoembolization, radio-embolization, radiofrequency ablation, radiotherapy at least six weeks prior to study entry; c.) Any number of previous lines of systemic therapy, providing that cytotoxic therapies (chemotherapy, PRRT) have been discontinued at least 4 weeks prior to study entry. Non-NET Cohort - - Healthy participants - Patients with histologically or cytologically proven diagnosis of any grade, any stage GI malignancies. Exclusion Criteria: NET Cohort - - Patients on treatment with cytotoxic agents (chemotherapy, PRRT). - Patients with renal insufficiency or congestive heart failure. - No other active malignancy within 3 years of enrolment except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission. Non-NET Cohort - Patients with GI malignancies with neuroendocrine differentiation. |
Country | Name | City | State |
---|---|---|---|
United States | H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
H. Lee Moffitt Cancer Center and Research Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of Successful Test Results Per Cohort | Investigators have designed the study to test the null hypothesis that the NETest has a sensitivity and specificity of 70% or less in NET patients. The sample size calculation has been based on the assumption that a sensitivity and specificity of greater than 90% would generate further interest in the test for unselected NET patients. Power and type 1 error will be 99% and 5% respectively. Under this model, 80 or more positive tests in the cohort of 100 patients with NETs would lead to the rejection of the null hypothesis, suggesting that the NETest is sensitive. Likewise, 80 or more negative tests in 100 patients without NETs will suggest that NETest is specific. An interim analysis will be performed to rule out the futility of the NETest. Futility will be defined as a rate of false positive or false negative >25%. Hence, if 12 or more false positives or negatives are observed among the first 50 participants, the study will be suspended, pending review by the investigators. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06155318 -
68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
|
||
Terminated |
NCT01994213 -
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
|
Phase 2 | |
Active, not recruiting |
NCT03980925 -
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
|
Phase 2 | |
Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT04852679 -
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
|
Phase 3 | |
Enrolling by invitation |
NCT05064150 -
Neuroendocrine Tumors - Patient Reported Outcomes
|
||
Active, not recruiting |
NCT04727723 -
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
|
||
Recruiting |
NCT06256705 -
Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort
|
N/A | |
Active, not recruiting |
NCT05477576 -
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
|
Phase 3 | |
Recruiting |
NCT04609592 -
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
|
Phase 1 | |
Recruiting |
NCT05701241 -
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
|
Phase 4 | |
Withdrawn |
NCT04915144 -
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
|
Phase 2 | |
Recruiting |
NCT04986085 -
Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
|
||
Active, not recruiting |
NCT05262556 -
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
|
Phase 1 | |
Completed |
NCT03017690 -
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
|